Certolizumab pegol in the treatment of Takayasu arteritis

Novikov, Pavel; Smitienko, Ilya; Sokolova, Maria; Alibaz-Oner, FATMA; Kaymaz-Tahra, Sema; Direskeneli, RAFİ; Moiseev, Sergey

doi:10.1093/rheumatology/key197

Certolizumab pegol in the treatment of Takayasu arteritis

Novikov P. I., Smitienko I. O., Sokolova M. V., Alibaz-Oner F., Kaymaz-Tahra S., Direskeneli H., ...Daha Fazla

RHEUMATOLOGY, cilt.57, sa.12, ss.2101-2105, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 57 Sayı: 12
Basım Tarihi: 2018
Doi Numarası: 10.1093/rheumatology/key197
Dergi Adı: RHEUMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2101-2105
Anahtar Kelimeler: TNF inhibitors, certolizumab pegol, Takayasu arteritis, ANTIRHEUMATIC DRUGS, CASES SERIES, MULTICENTER, PREGNANCY, INHIBITORS, INFLIXIMAB, EFFICACY, CRITERIA, STANDARD, ALPHA
Marmara Üniversitesi Adresli: Evet

Özet

Objectives. Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA).